ABBOTT LABORATORIES Revenue by Geography
No Revenue by Geography for ABT on this site yet.
- 2025-12-31: Others Not split by product in the filing$44.33B100.00%; Total revenue $44.33B.
- 2024-12-31: Others Not split by product in the filing$41.95B100.00%; Total revenue $41.95B.
- 2023-12-31: Others Not split by product in the filing$40.11B100.00%; Total revenue $40.11B.
- 2022-12-31: Others Not split by product in the filing$43.65B100.00%; Total revenue $43.65B.
Source checked: the stored Revenue by Geography page for ABT.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $44.33B 100.00% | $44.33B |
| 2024-12-31 | Not split by product in the filing $41.95B 100.00% | $41.95B |
| 2023-12-31 | Not split by product in the filing $40.11B 100.00% | $40.11B |
| 2022-12-31 | Not split by product in the filing $43.65B 100.00% | $43.65B |
| 2021-12-31 | Not split by product in the filing $43.08B 100.00% | $43.08B |
| 2020-12-31 | Not split by product in the filing $34.61B 100.00% | $34.61B |
| 2019-12-31 | Not split by product in the filing $31.90B 100.00% | $31.90B |
| 2018-12-31 | Not split by product in the filing $30.58B 100.00% | $30.58B |
| 2017-12-31 | Not split by product in the filing $27.39B 100.00% | $27.39B |
| 2016-12-31 | Not split by product in the filing $20.85B 100.00% | $20.85B |
| 2015-12-31 | Not split by product in the filing $20.41B 100.00% | $20.41B |
| 2014-12-31 | Not split by product in the filing $20.25B 100.00% | $20.25B |
| 2013-12-31 | Not split by product in the filing $19.66B 100.00% | $19.66B |
| 2012-12-31 | Not split by product in the filing $19.05B 100.00% | $19.05B |
| 2011-12-31 | Not split by product in the filing $21.41B 100.00% | $21.41B |
| 2010-12-31 | Not split by product in the filing $35.17B 100.00% | $35.17B |
| 2009-12-31 | Not split by product in the filing $30.76B 100.00% | $30.76B |
| 2008-12-31 | Not split by product in the filing $29.53B 100.00% | $29.53B |
| 2007-12-31 | Not split by product in the filing $25.91B 100.00% | $25.91B |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-03-31 | Not split by product $11.16B 100.00% | $11.16B |
| 2025-12-31 | Not split by product $11.46B 100.00% | $11.46B |
| 2025-09-30 | Not split by product $11.37B 100.00% | $11.37B |
| 2025-06-30 | Not split by product $11.14B 100.00% | $11.14B |
| 2025-03-31 | Not split by product $10.36B 100.00% | $10.36B |
| 2024-12-31 | Not split by product $10.97B 100.00% | $10.97B |
| 2024-09-30 | Not split by product $10.63B 100.00% | $10.63B |
| 2024-06-30 | Not split by product $10.38B 100.00% | $10.38B |
| 2024-03-31 | Not split by product $9.96B 100.00% | $9.96B |
| 2023-12-31 | Not split by product $10.24B 100.00% | $10.24B |
| 2023-09-30 | Not split by product $10.14B 100.00% | $10.14B |
| 2023-06-30 | Not split by product $9.98B 100.00% | $9.98B |
| 2023-03-31 | Not split by product $9.75B 100.00% | $9.75B |
| 2022-12-31 | Not split by product $10.09B 100.00% | $10.09B |
| 2022-09-30 | Not split by product $10.41B 100.00% | $10.41B |
| 2022-06-30 | Not split by product $11.26B 100.00% | $11.26B |
| 2022-03-31 | Not split by product $11.89B 100.00% | $11.89B |
| 2021-12-31 | Not split by product $11.47B 100.00% | $11.47B |
| 2021-09-30 | Not split by product $10.93B 100.00% | $10.93B |
| 2021-06-30 | Not split by product $10.22B 100.00% | $10.22B |
| 2021-03-31 | Not split by product $10.46B 100.00% | $10.46B |
| 2020-12-31 | Not split by product $10.70B 100.00% | $10.70B |
| 2020-09-30 | Not split by product $8.85B 100.00% | $8.85B |
| 2020-06-30 | Not split by product $7.33B 100.00% | $7.33B |
| 2020-03-31 | Not split by product $7.73B 100.00% | $7.73B |
| 2019-12-31 | Not split by product $8.31B 100.00% | $8.31B |
| 2019-09-30 | Not split by product $8.08B 100.00% | $8.08B |
| 2019-06-30 | Not split by product $7.98B 100.00% | $7.98B |
| 2019-03-31 | Not split by product $7.54B 100.00% | $7.54B |
| 2018-12-31 | Not split by product $7.76B 100.00% | $7.76B |
| 2018-09-30 | Not split by product $7.66B 100.00% | $7.66B |
| 2018-06-30 | Not split by product $7.77B 100.00% | $7.77B |
| 2018-03-31 | Not split by product $7.39B 100.00% | $7.39B |
| 2017-12-31 | Not split by product $7.59B 100.00% | $7.59B |
| 2017-09-30 | Not split by product $6.83B 100.00% | $6.83B |
| 2017-06-30 | Not split by product $6.64B 100.00% | $6.64B |
| 2017-03-31 | Not split by product $6.33B 100.00% | $6.33B |
| 2016-12-31 | Not split by product $5.33B 100.00% | $5.33B |
| 2016-09-30 | Not split by product $5.30B 100.00% | $5.30B |
| 2016-06-30 | Not split by product $5.33B 100.00% | $5.33B |
| 2016-03-31 | Not split by product $4.88B 100.00% | $4.88B |
| 2015-12-31 | Not split by product $5.19B 100.00% | $5.19B |
| 2015-09-30 | Not split by product $5.15B 100.00% | $5.15B |
| 2015-06-30 | Not split by product $5.17B 100.00% | $5.17B |
| 2015-03-31 | Not split by product $4.90B 100.00% | $4.90B |
| 2014-12-31 | Not split by product $5.36B 100.00% | $5.36B |
| 2014-09-30 | Not split by product $5.08B 100.00% | $5.08B |
| 2014-06-30 | Not split by product $5.06B 100.00% | $5.06B |
| 2014-03-31 | Not split by product $4.75B 100.00% | $4.75B |
| 2013-12-31 | Not split by product $5.07B 100.00% | $5.07B |
| 2013-09-30 | Not split by product $4.80B 100.00% | $4.80B |
| 2013-06-30 | Not split by product $4.93B 100.00% | $4.93B |
| 2013-03-31 | Not split by product $4.85B 100.00% | $4.85B |
| 2012-12-31 | Not split by product $5.63B 100.00% | $5.63B |
| 2012-09-30 | Not split by product $5.26B 100.00% | $5.26B |
| 2012-06-30 | Not split by product $5.31B 100.00% | $5.31B |
| 2012-03-31 | Not split by product $5.28B 100.00% | $5.28B |
| 2011-12-31 | Not split by product $10.38B 100.00% | $10.38B |
| 2011-09-30 | Not split by product $9.82B 100.00% | $9.82B |
| 2011-06-30 | Not split by product $9.62B 100.00% | $9.62B |
| 2011-03-31 | Not split by product $9.04B 100.00% | $9.04B |
| 2010-12-31 | Not split by product $9.97B 100.00% | $9.97B |
| 2010-09-30 | Not split by product $8.67B 100.00% | $8.67B |
| 2010-06-30 | Not split by product $8.83B 100.00% | $8.83B |
| 2010-03-31 | Not split by product $7.70B 100.00% | $7.70B |
| 2009-12-31 | Not split by product $8.79B 100.00% | $8.79B |
| 2009-09-30 | Not split by product $7.76B 100.00% | $7.76B |
| 2009-06-30 | Not split by product $7.49B 100.00% | $7.49B |
| 2009-03-31 | Not split by product $6.72B 100.00% | $6.72B |
| 2008-12-31 | Not split by product $7.95B 100.00% | $7.95B |
| 2008-09-30 | Not split by product $7.50B 100.00% | $7.50B |
| 2008-06-30 | Not split by product $7.31B 100.00% | $7.31B |
| 2008-03-31 | Not split by product $6.77B 100.00% | $6.77B |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |